Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Insight into the mechanism of laquinimod action.
Power estimation for non-standardized multisite studies.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Studying both sexes: a guiding principle for biomedicine.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US

Pages